23andMe: Phase 1 Results from the First-in-Human Phase 1/2a Study of Solid Tumor Therapy

 

• First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignancies
• Recommended dose selected for evaluation of anti-tumor activity in the ongoing Phase 2a portion of the Phase 1/2a study

https://www.biospace.com/article/releases/23andme-announces-phase-1-results-from-the-first-in-human-phase-1-2a-study-of-23me-00610-an-investigational-antibody-targeting-cd200r1/